-
公开(公告)号：US10519191B2
公开(公告)日：2019-12-31
申请号：US14952526
申请日：2015-11-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Peng Dai , Jiang Long , Xuechao Xing , Guoqiang Wang
Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
-
92.发明申请
公开(公告)号：US20190337923A1
公开(公告)日：2019-11-07
申请号：US16400529
申请日：2019-05-01
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun MA , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D417/14 , C07D409/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US20190194245A1
公开(公告)日：2019-06-27
申请号：US16222380
申请日：2018-12-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10323060B2
公开(公告)日：2019-06-18
申请号：US15439303
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Xuechao Xing , Guoqiang Wang , Ruichao Shen , Jing He
IPC: A61K31/575 , A61K31/58 , C07J9/00 , C07J43/00
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US20180362503A1
公开(公告)日：2018-12-20
申请号：US15988806
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D471/04 , C07D471/08
CPC classification number: C07D401/14 , C07D417/14 , C07D451/02 , C07D451/06 , C07D471/04 , C07D471/08
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20180099957A1
公开(公告)日：2018-04-12
申请号：US15724919
申请日：2017-10-04
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jun Ma , Guoqiang Wang , Bin Wang , Xuechao Xing , Ruichao Shen , Jing He , Yat Sun Or
IPC: C07D413/14 , C07D413/12 , C07D261/08
CPC classification number: C07D413/14 , C07D261/08 , C07D413/12 , C07D417/14
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
97.发明申请BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF 审中-公开双酸衍生物作为FXR / TGR5激动剂及其使用方法
公开(公告)号：US20160289262A1
公开(公告)日：2016-10-06
申请号：US15085800
申请日：2016-03-30
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Abstract translation: 本发明还提供包含这些化合物的药物组合物和使用该化合物治疗FXR介导的或TGR5介导的疾病或病症的方法。
-
98.发明申请
公开(公告)号：US20160145296A1
公开(公告)日：2016-05-26
申请号：US14952526
申请日：2015-11-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Peng Dai , Jiang Long , Xuechao Xing , Guoqiang Wang
CPC classification number: C07J43/003 , A61P1/16 , C07J9/00 , C07J9/005 , C07J17/00 , C07J31/006 , C07J41/0055 , C07J41/0061 , C07J41/0088 , C07J41/0094 , C07J51/00
Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
Abstract translation: 本发明涉及式（IA）和式（IB）的化合物及其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9和m如本文所定义，药物组合物 包括这些化合物和这些化合物用于治疗TGR5介导的疾病或病症的方法。
